PMID- 17564066
OWN - NLM
STAT- MEDLINE
DCOM- 20070626
LR  - 20121115
IS  - 0021-5252 (Print)
IS  - 0021-5252 (Linking)
VI  - 60
IP  - 6
DP  - 2007 Jun
TI  - [Recent advances and limitations of medical treatment on heart failure].
PG  - 484-7
AB  - Main part of the management of chronic heart failure is pharmaceutical therapy. 
      In patients with chronic heart failure due to left ventricular systolic 
      dysfunction, enhanced activation of neurohormonal systems including sympathetic 
      nerve and renin-angiotensin-aldosterone system plays the most important role in 
      its progression and poor prognosis. Therefore, principle of treatment of chronic 
      heart failure is inhibition of the elevated neurohormonal activity. Angiotensin 
      converting enzyme inhibitors and beta blockers are class I drugs of choice. In 
      patients who can not tolerate angiotensin converting enzyme inhibitors, 
      angiotensin II receptor blockers are used as replacement. In patients with severe 
      heart failure [New York Heart Association (NYHA) class > III], aldosterone 
      antagonists are added. Diuretics are also class I drug necessary for an 
      improvement of symptoms of heart failure. Recently, implantable cardioverter 
      defibrillator (ICD) and cardiac resynchronization therapy (CRT) are implanted 
      more frequently, because volume of evidence indicates benefits of these 
      non-pharmacological treatments. In this paper, recent advance in medical therapy 
      for patients with heart failure and its limitation is discussed.
FAU - Momomura, Shin-ichi
AU  - Momomura S
AD  - Cardiovascular Division, Omiya Medical Center, Jichi Medical University, Saitama, 
      Japan.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Kyobu Geka
JT  - Kyobu geka. The Japanese journal of thoracic surgery
JID - 0413533
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Diuretics)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - *Defibrillators, Implantable
MH  - Diuretics/therapeutic use
MH  - Heart Failure/drug therapy/etiology/prevention & control/*therapy
MH  - Humans
MH  - Mineralocorticoid Receptor Antagonists/therapeutic use
MH  - Ventricular Dysfunction, Left/complications
EDAT- 2007/06/15 09:00
MHDA- 2007/06/27 09:00
CRDT- 2007/06/15 09:00
PHST- 2007/06/15 09:00 [pubmed]
PHST- 2007/06/27 09:00 [medline]
PHST- 2007/06/15 09:00 [entrez]
PST - ppublish
SO  - Kyobu Geka. 2007 Jun;60(6):484-7.